Business Wire

VA-DXC-TECHNOLOGY

21.5.2020 15:02:13 CEST | Business Wire | Press release

Share
DXC Introduces Corporate Incident Response Application to Help Businesses Proactively Reduce Risk

DXC Technology (NYSE: DXC) today introduced its Corporate Incident Response (CIR) application for ServiceNow to enable organizations like Banco Santander, one of the largest retail and commercial banks in the world, and the Nordex Group, one of the world’s largest wind turbine manufacturers, to quickly and proactively identify, address and manage important non-IT corporate incidents, such as those related to facilities, physical security, and environment, health and safety. The application, built on the ServiceNow platform, allows businesses to reduce their risk profiles and overcome situations before they evolve into companywide crises.

The CIR application provides an end-to-end workflow management solution to manage, track and respond to non-IT-related issues in an efficient, standardized manner.

“In today’s world, business disruptions are inevitable. While operational resilience has been around for years, a change in mindset is required in order to prevent, respond to, recover from, and most importantly, learn from and adapt after crises occur,” said Dan Stoks, vice president, Global ServiceNow Practice, DXC Technology. “The Corporate Incident Response application can work with ServiceNow’s integrated risk management and other workflows to enable organizations to securely manage crisis response workflows and risks to the business.”

Key features of the solution:

  • Situation rooms — provide a central point of collaboration for dispersed organizations to orchestrate response teams and plans and monitor and evaluate the overall picture.
  • App notifications — provide the ability to send companywide notifications, such as alerts, push notifications, email and SMS to predefined groups as well as external partners and customers.
  • 360-degree view — provides the management team with a 360-degree view of where the organization stands on corporate-related incidents, so they can make fact-based decisions that reduce their overall risk profile.

Banco Santander Streamlines Crisis Management Systems with DXC CIR Application

Banco Santander wanted a single platform to manage its global facility and security processes and replace its previous system with a new, digitized platform. Using the DXC CIR application with ServiceNow, Santander streamlined its processes with better-performing facility, security and crisis management systems and improved user experiences for its managers and end users. It also benefited from better insights and greater transparency in its global facility and security services.

“The consolidation of existing and new facility management capabilities to a new platform was a crucial part of our business transformation journey,” said Galo Gilarranz Vicente, Real Estate, General Services and Security, Banco Santander. “DXC’s CIR application has allowed us to reduce costs by rationalizing the global application landscape, standardize our processes and increase employee efficiency with automation.”

The Nordex Group Improves Worker Safety with DXC’s Health, Safety and Environmental Management Business Expertise

The Nordex Group tapped the DXC Health, Safety and Environment Suite (HSE) for ServiceNow, which is part of DXC’s CIR portfolio, to create a safety-driven culture throughout its global operations. With the DXC suite, the Nordex Group experienced a more streamlined process to reduce worker hazards and prevent incidents before they occur.

“Nordex is committed to worker safety, implementing proper processes to prevent and quickly respond to work-related incidents,” said Philipp Marten, program manager, Business Systems, Nordex Group. “With DXC’s HSE solution, we were able to reduce the complexity of our system, streamline reporting and create a safer work environment throughout our global operations.”

DXC is offering this application for free for 120 days to complement and enhance the capabilities of ServiceNow Emergency Response Management applications.

“Operational risk management is a crucial part of how ServiceNow enables resilience for our customers for both IT and non-IT operations,” said David Parsons, senior vice president, Global Alliances and Channel Ecosystem, ServiceNow. “Corporate Incident Response from DXC Technology exemplifies the innovative applications that extend the value of the Now Platform and our Risk and Business Continuity portfolio to serve critical and emerging use cases for joint customers enterprise-wide.”

To learn more and download the CIR for ServiceNow application, click here .

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye